Key Summary Points {#FPar1}
==================

The quality of early evidence favoring the different treatment options needs to be apprised for informed decision-making.We performed a comprehensive systematic literature search and appraisal of early clinical evidence for the therapeutic management of SARS-CoV-2 infection.An overview on the difference in recommendations and the evidence base for arriving at the recommendations by various guidelines have been provided.The insights from quality of early evidence will also assist in mounting a better response to future pandemics.

Introduction {#Sec1}
============

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, which started as a cluster of pneumonia cases in Wuhan, China, in December 2019 was declared a pandemic by the World Health Organization (WHO) on March 11, 2020 \[[@CR1]\]. As per the data from the WHO, as of May 31, 2020, it had infected 5.9 million people globally, with approximately 3,67,000 people succumbing to the infection \[[@CR2]\]. After isolation and sequence analysis, the causative virus was grouped into the coronavirus (CoV) family, consisting of RNA viruses that had already caused three different outbreaks of pneumonia in the last 2 decades. The severe acute respiratory syndrome (SARS) that broke out in 2003 was caused by SARS-CoV, whereas the Middle East respiratory syndrome (MERS) that broke out in 2012 was caused by the MERS-CoV \[[@CR3]\]. The viral etiologic agent was named SARS-CoV-2 by the international viral classification commission, and the disease was officially named COVID-19 by the WHO \[[@CR4]\].

Clinical observation with SARS-CoV-2 revealed mild illness in a majority of the patients and severe lung injury or multiorgan failure in approximately 5% of the patients, with a case fatality ratio of 1.4% \[[@CR5]\]. The pathologic findings in severely or critically ill patients revealed manifestations of shock and sepsis, which is hypothesized to be caused by the virus-induced "cytokine storm" \[[@CR6]\]. The levels of proinflammatory cytokines and chemokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, granulocyte-colony-stimulating factor, interferon-gamma-induced protein-10, monocyte chemoattractant protein-1 and macrophage inflammatory proteins 1-α, were reported to be elevated from early clinical observations, substantiating the "cytokine storm" hypothesis. In cases with mild infection, the resident macrophages in the lung initiate an inflammatory response culminating in the successful containment of the replication of SARS-CoV-2. However, in patients with severe COVID-19 infection, the pathologic findings revealed the impairment of the epithelial-endothelial barrier, leading to a large exudate into the alveolar cavity \[[@CR6]\]. The disruption of the endothelial lining initiates a vicious cycle of tissue damage because of the inflammatory response facilitated by the accumulation of regional macrophages, neutrophils and lymphocytes, resulting in a "cytokine storm." Apart from the epithelial cells, virus multiplication in lung capillary endothelial cells has also been reported, which may lead to exudation of plasma in the alveolar cavity leading to microvascular dysfunction. Abnormal coagulation leading to disseminated intravascular coagulation has also been reported in the majority of fatal cases suggesting coagulopathy due to viral sepsis as a possible terminal clinical manifestation. The suggested reasons for coagulopathy in COVID-19 patients include but are not limited to viral sepsis, cytokine storm and multi-organ failure \[[@CR4], [@CR7]\]. The incidence of venous thromboembolism is also reported to be high in COVID-19 patients treated in the intensive care unit (ICU), and hence multiple treatment guidelines recommend prophylactic treatment for venous thromboembolism to minimize fatal outcomes \[[@CR8]\].

Elderly patients and patients with comorbidities are more susceptible to severe COVID-19 infection \[[@CR9]\]. The current case fatality rate of COVID-19 is lower than during the 1918 influenza pandemic but higher than during the 1957 influenza pandemic \[[@CR10]\]. However, among the recent outbreaks of CoV infections (SARS-CoV and MERV), SARS-CoV-2 was found to be much more adoptable to different geographic locations with a higher propensity for person-to-person transfer \[[@CR11]\].

The typical response to a pandemic involves both short- and long-term plans to minimize the case fatality rate and reduce the response time for future pandemics \[[@CR11]\]. The current strategies for reducing fatality mainly involve symptomatic management and therapeutic interventions \[[@CR4]\]. The choices available for therapeutic management were mainly based on immune modulators acting on inflammatory tissue damage and antiviral drugs. Although immune modulators can minimize the inflammatory effects, they may suppress the innate immune responses, leading to delay in viral clearance \[[@CR11]\]. Antiviral drugs that were proven to be effective in the treatment of RNA virus infection are currently being explored as possible treatment options. However, in the era of evidence-based medicine, the response to a pandemic typically involves repurposing existing drugs targeting specific steps in the pathogenesis. The early evidence base for the successful treatment of COVID-19 may provide insights into mounting a response to future pandemics. Furthermore, the gaps and drawbacks in the early evidence may also provide insights into mounting appropriate responses with respect to the generation of clinical evidence in case of future pandemics. Unlike previous pandemics, the current one is in the era of evidence-based medicine wherein the responses by various national and international nodal organizations will be based only on the quality of evidence. Furthermore, unlike other therapy areas, in case of pandemics, the treatment guidelines may undergo rapid paradigm shifts as the clinical evidence landscape gains maturity with respect to treatment options and end points for assessing efficacy. Hence, in this present study, we evaluated the quality of early clinical evidence currently guiding the treatment strategies for COVID-19 and the therapeutic recommendations of different treatment guidelines. We also provided a perspective on the quality of early evidence and its probable utility for future responses to pandemics.

Methods {#Sec2}
=======

This systematic literature review aimed to answer the following questions: What are the different pharmacologic interventions used in the therapeutic management of patients with COVID-19 infection? What is the quality of the evidence on which the different pharmacologic interventions currently practiced in clinical settings for the therapeutic management of COVID-19 are based? Which drug/pharmacologic interventions used for the therapeutic management of patients with COVID-19 have sufficient evidence to support their use in clinical practice?

Data Sources and Searches {#Sec3}
-------------------------

To ensure the retrieval of all relevant studies, we searched PubMed with a broad key word "COVID-19." We also included COVID-19 studies in preprint servers, such as MedRxiv and BioRxiv (<https://connect.biorxiv.org/relate/content/181>). Duplicate studies were removed, and a consolidated Excel sheet was prepared for screening. Any study evaluating a therapeutic drug in in vivo or in vitro model was considered a relevant evidence base and graded based on the hierarchy of an evidence-based pyramid into pre-clinical, case report, case series, cross-sectional, retrospective cohort, prospective cohort, randomized controlled trials (RCTs), meta-analysis and systematic reviews. This systematic literature review was registered in Prospero (CRD42020180148). This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Study Selection {#Sec4}
---------------

The systematic review yielded a total of 4027 articles from PubMed and 1591 articles from preprint servers (Fig. [1](#Fig1){ref-type="fig"}). Primary screening with the title and abstract revealed a total of 569 relevant articles. On the basis of the full-text screening, a total of 22 studies (Table [1](#Tab1){ref-type="table"}) were included for the evidence synthesis. The studies included for appraisal ranged from case reports to RCTs.Fig. 1PRISMA study selection flowchartTable 1Early clinical evidence for the treatment of SARS-CoV-2S. no.Study nameStudy typeIntervention (*n*)DoseControl group (*n*)DoseOutcome/end pointsConclusion1Gautret et al. \[[@CR17]\]Prospective cohort studyHydroxychloroquine alone or in combination with azithromycin (26)600-mg hydroxychloroquine daily and 500-mg azithromycin on day 1 followed by 250 mg for days 2--5Supportive care (16)--Virologic cureFavors treatment with azithromycin2Chen et al. \[[@CR21]\]Prospectively randomized studyHydroxychloroquine (15)400-mg hydroxychloroquine for 5 days plus conventional treatmentConventional supportive treatment (15)--Virologic cureNo significant difference in the rates of virologic cure3Zhaowei Chen et al. \[[@CR18]\]Randomized controlled studyHydroxychloroquine (31)400-mg hydroxychloroquine for 5 daysStandard supportive care (31)--Virologic and clinical outcomesTreatment with hydroxychloroquine significantly improved virologic cure and alleviation of clinical symptoms4Molina et al. \[[@CR22]\]Single-arm, prospective, cohort studyHydroxychloroquine and azithromycin (11)600-mg hydroxychloroquine daily for 10 days and 500-mg azithromycin on day 1 followed by 250 mg for days 2--5--Virologic cureNo virologic cure in majority of the patients5Chorin et al. \[[@CR20]\]Single-arm studyHydroxychloroquine (84)--SafetyHydroxychloroquine extended the QT interval, increasing the risk of arrythmia6Million et al. \[[@CR19]\]Single-arm, retrospective, cohort studyHydroxychloroquine and azithromycin (1061)200 mg 3 times a day for 10 days and 500-mg azithromycin on day 1 followed by 250 mg for days 2--5--Virologic and clinical cureHigh rates of virologic cure and clinical alleviation of symptoms were observed in patients7Magognoli et al. \[[@CR23]\]Retrospective, propensity-score-matched cohortHydroxychloroquine and azithromycin (210)Not availableSupportive care (158)--Death and rates of ventilationLower rates of death in the control groupSimilar rates of ventilation in the intervention and control groups8Tang et al. \[[@CR24]\]Randomized controlled studyHydroxychloroquine plus standard of care (75)1200 mg daily for 3 days followed by 800 mg dailyStandard of care alone (75)--Virologic cureVirologic cure rates were similar in both the intervention and control groups after 28 days of treatment9Holshue et al. \[[@CR28]\]Case reportRemdesivir (1)Not available----Virologic cureReduction in viral load observed; response might be due to immunity or supportive care10Grein et al. \[[@CR29]\]Single-arm, prospective cohortRemdesivir (61)200 mg on day 1 and 100 mg for days 2--9----Clinical cure68% of the patients experienced clinical improvement of symptoms11Wang et al. \[[@CR30]\]Randomized controlled trialRemdesivir (158)200 mg on day 1 and 100 mg for days 2--9Supportive care (79)-Clinical cureNo significant difference in the time to clinical improvement among the groups12Zha et al. \[[@CR34]\]Prospective cohortCorticosteroid (11)40-mg methylprednisolone once daily or twice a daySupportive care (20)--Clinical cureNo significant improvement in patients treated with corticosteroids13Wang et al. \[[@CR36]\]Prospective cohortEarly, low-dose, corticosteroids (26)1--2 mg/kg/day for 5--7 daysSupportive care (20)Clinical cureSignificant improvement in patients treated with corticosteroids14Lu et al. \[[@CR37]\]Retrospective cohortAdjuvant corticosteroid (151)hydrocortisone-equivalent dosage range: 100--800 mg/dSupportive care (93)--Clinical cureNo significant difference among the treatment groups15Shen et al. \[[@CR38]\]Case seriesConvalescent plasma (5)\> 1:1000 end point dilution titer--Virologic and clinical cureResolution of clinical symptoms and reduction in viral load16Duan et al. \[[@CR39]\]Case seriesConvalescent plasma (10)\> 1:640 neutralizing antibody titer--Virologic and clinical cureResolution of clinical symptoms and reduction in viral load17Young et al. \[[@CR40]\]Case reportConvalescent plasma (2)Optical density of IgG of 0.586 divided into 2 doses at 12-h interval--Virologic and clinical cureResolution of clinical symptoms and reduction in viral load18Zhu et al. \[[@CR44]\]RCTArbidol (16)0.2-g arbidol 3 times a dayLopinavir/ritonavir (34)400 mg/100 mg of lopinavir/ritonavir twice a day for a weekVirologic cureArbidol is superior in cases with mild-to-moderate SARS-CoV infection19Li et al. \[[@CR45]\]RCTArbidol and lopinavir/ritonavir (69)200-mg lopinavir and 50-mg rotinavir twice a day or 200 mg arbidol 3 times a dayNo antiviral drug (17)--Virologic cureNo significant difference among the treatment groups20Ye et al. \[[@CR43]\]Prospective cohortLopinavir/ritonavir plus adjuvant treatment (42)80-mg lopinavir and 20-mg ritonavirAdjuvant treatment alone (5)--Clinical cureTreatment with lopinavir/ritonavir led to normalization of body temperature21Xu et al. \[[@CR41]\]Prospective cohortTocilizumab (20)400--800 mg----Clinical cureAll the patients experienced normalization of body temperature and were very low stable after 1 day of treatment22Luna et al. \[[@CR42]\]Case reportTocilizumab (1)8 mg/kg--Clinical curePatient's SpO~2~ improved from 80 to 97% and the patient was apyrexic

Data Extraction and Quality Assessment {#Sec5}
--------------------------------------

The evidence was categorized as very low, low, moderate and strong as per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profile (Table [2](#Tab2){ref-type="table"}). As per the GRADE system, evidence from RCTs was considered to be strong evidence, which is down-rated if there are serious limitations, imprecision, inconsistency, indirectness or publication bias. Observational studies are rated as low quality and up-rated if the magnitude of the effect is large, has minimal confounders and there is a dose-dependent effect \[[@CR12]\].Table 2GRADE evidence profileOutcomeCertainty assessmentNo. of patientsEffectCertaintyStudy IDStudy designRisk of biasInconsistencyIndirectnessImprecisionOther considerationsInterventionComparatorRelative (95% CI)Absolute (95% CI)MortalityChen et al. \[[@CR21]\]RCTSeriousNot seriousNot seriousVery seriousNone0/150/15--Very lowFailure of virologic clearanceChen et al. \[[@CR21]\]RCTSeriousNot seriousSeriousVery seriousNone2/151/15RR 2.0 (0.2--20)Very lowClinical improvementZhaowei Chen et al. \[[@CR18]\]RCTSeriousNot seriousSeriousSeriousNone25/3117/31RR 1.47 (1.02--2.11)Very lowVirologic cureGautret et al. \[[@CR17]\]Prospective cohortVery seriousSeriousNot seriousSeriousNone70%12.5%RR 16.33 (2.8--95.26)Very lowVirologic cureMolina et al. \[[@CR22]\]Single-arm studyVery seriousSeriousSeriousSeriousNone2/11------Very lowMortalityMolina et al. \[[@CR22]\]Single-arm studyVery seriousSeriousSeriousSeriousNone1/11------Very lowQT intervalChorin et al. \[[@CR20]\]Single-arm studyVery seriousSeriousSeriousSeriousNone11%------Very lowMortalityMillion et al. \[[@CR19]\]Single-arm, retrospective, cohort studyVery seriousSeriousSeriousNot seriousNone8/1061------Very lowVirologic cureMillion et al. \[[@CR19]\]Single-arm, retrospective, cohort studyVery seriousSeriousSeriousNot seriousNone973/1061------Very lowMortalityMagognoli et al. \[[@CR23]\]Retrospective, propensity-score-matched cohortVery seriousNot seriousNot seriousNot seriousNone51/21018/158RR 2.49 (1.39--4.47)--Very lowRates of ventilationMagognoli et al. \[[@CR23]\]Retrospective, propensity-score-matched cohortVery seriousNot seriousSeriousNot seriousNone21/21022/158RR 0.69 (0.36--1.29)--Very lowVirologic cureTang et al. \[[@CR24]\]Randomized controlled studyVery seriousSeriousSeriousNot seriousNone64/7561/75RR 1.33 (0.56--3.16)--Very lowClinical cureHolshue et al. \[[@CR28]\]Case reportVery seriousNot seriousNot seriousVery seriousNone1/1------Very lowExtubation of mechanical ventilationGrein et al. \[[@CR29]\]Single-arm, prospective cohort17/30Very lowMortalityGrein et al. \[[@CR29]\]Single-arm, prospective cohortVery seriousSeriousSeriousSeriousNone7/61------Very lowBody temperatureWang et al. \[[@CR36]\]Prospective cohortVery seriousSeriousSeriousSeriousNone2.06 ± 0.285.29 ± 0.70----Very lowMortalityLu et al. \[[@CR37]\]Retrospective cohortVery seriousSeriousSeriousSeriousNone12/315/31RR 3.2 (0.98--10.89)--Very lowBody temperature normalizationShen et al. \[[@CR38]\]Case seriesNot seriousNot seriousVery seriousNot seriousNone4/5------Very lowVirologic cureShen et al. \[[@CR38]\]Case seriesNot seriousNot seriousVery seriousNot serious5/5------Very lowClinical cureDuan et al. \[[@CR39]\]Case seriesNot seriousNot seriousVery seriousNot serious10/10------Very lowAbsorption of pulmonary lesionsDuan et al. \[[@CR39]\]Case seriesNot seriousNot seriousVery seriousNot serious10/10------Very lowVirologic cureYoung et al. \[[@CR40]\]Case seriesNot seriousNot seriousVery seriousNot serious2/2/------Very lowVirologic cureZhu et al. \[[@CR44]\]RCTSeriousNot seriousNot seriousNot serious16/1619/34RR 26.23 (1.45--472.69)--Very lowVirologic cureLi et al. \[[@CR45]\]RCTSeriousNot seriousSeriousSerious25/697/17RR 0.81 (0.27--2.39)--Very lowDays to normalization of body temperatureYe et al. \[[@CR43]\]Prospective cohortVery seriousNot seriousSeriousNot serious4.8 ± 1.947.3 ± 1.53----Very lowBody temperature normalizationXu et al. \[[@CR41]\]Prospective cohortVery seriousNot seriousSeriousNot serious20/20------Very lowVirologic cureLuna et al. \[[@CR42]\]Case reportVery seriousVery seriousNot seriousNot serious1/1------Very low*RR* relative risk

Data Synthesis and Analysis {#Sec6}
---------------------------

The evidence base was individually rated for different end points within a single study. Studies synthesizing the previous evidence base along with the expert opinions were also considered as an evidence base. The efficacy end points considered in pre-clinical studies included reduction in viral copy numbers evaluated by real-time polymerase chain reaction (RT-polymerase chain reaction \[PCR\]) and lack of viral nucleoprotein assessed by immunofluorescence. However, in case of clinical studies, the various end points of efficacy assessed were either clinical cure (time to body temperature normalization, duration of cough, death or clinical worsening of disease) or virologic cure (negative RT-PCR).

Results {#Sec7}
=======

Pharmacologic Interventions {#Sec8}
---------------------------

Based on the systematic review of published evidence, the different pharmacologic interventions explored for the therapeutic management of patients with COVID-19 were chloroquine/hydroxychloroquine, remdesivir, arbidol, lopinavir, ritonavir, glucocorticoids, immune modulators, immunoglobulin/plasma therapy, tissue plasminogen activator, recombinant erythropoietin, tocilizumab, baricitinib, ivermectin, tetracyclines, statins, homoharringtonine and metronidazole. All the drugs that have been explored as therapeutic options were previously used for the treatment of other clinical conditions. Hence, the evidence base does not follow the conventional pre-clinical-early clinical (phases I and II) phase III studies. On the contrary, the drugs are repurposed, and hence the main aims of later-stage clinical trials are to reposition the drug for COVID-19 (repositioning clinical trials) \[[@CR13]\].

Chloroquine and Hydroxychloroquine {#Sec9}
----------------------------------

Chloroquine is a 9-aminoquinoline, which is a weak base and facilitates an antimicrobial effect by increasing the pH of acidic vesicles. It has been safely used for the treatment of malaria, amoebiasis and autoimmune diseases \[[@CR14]\]. The first evidence of its activity against CoV was provided by Vincent et al. in Vero E6 cells against SARS-CoV. They confirmed the prophylactic effect of chloroquine in Vero E6 cells that were pretreated with 10 μM of chloroquine, which reduced the infectivity by 100% compared with the control. Similarly, the addition of 0.1--1 μM of chloroquine after infection reduced the infection by 50%, suggesting the probable therapeutic effect of chloroquine in SARS-CoV infection \[[@CR14]\]. The anti-SARS-CoV-2 activity of chloroquine was assessed by Wang et al. in the Vero E6 cell line. The time-of-addition assay suggested a probable role of chloroquine at the entry and post-entry stages of SARS-CoV-2 infection. The effective concentration (EC~90~) was found to be 6.90 μM, which is clinically achievable with the administration of 500-mg chloroquine \[[@CR15]\]. In pharmacokinetic modeling studies, hydroxychloroquine, which is an analog of chloroquine, was found to be more potent than chloroquine with a better safety profile \[[@CR16]\].

The first clinical evidence of efficacy was reported by Gautret et al. from a cohort of French patients who were treated with 600 mg of hydroxychloroquine. The study included 42 patients (26 patients treated with hydroxychloroquine and 16 patients in the control group) who were confirmed to be positive for SARS-CoV-2 by RT-PCR. Of the 20 patients treated with hydroxychloroquine available for efficacy assessment, 14 (70%) patients experienced virologic cure after 6 days of treatment, whereas only 2 (12.5%) patients in the control group were negative for SARS-CoV-2 after 6 days of treatment. A subgroup of patients in the hydroxychloroquine group was also treated with azithromycin (6 patients), and all of them experienced virologic cure, suggesting a better efficacy for hydroxychloroquine in combination with azithromycin than hydroxychloroquine alone (100% vs. 57%, respectively) \[[@CR17]\].

The first evidence of the efficacy of hydroxychloroquine from an RCT was published recently in the preprint server MedRxiv. The study recruited 62 patients positive for SARS-CoV-2 and randomly divided them into the test (hydroxychloroquine) and control (placebo) groups. Comparison of radiologic findings revealed that 61.3% of the patients in the hydroxychloroquine group showed significant improvement, whereas only 16.1% of those in the control group had significant improvement. The body temperature recovery time was also significantly reduced in the hydroxychloroquine group (2.2 \[0.4\] days) compared with the control group (3.2 \[1.3\] days). Similarly, cough remission time was also significantly reduced in the hydroxychloroquine group \[[@CR18]\].

The efficacy of hydroxychloroquine in combination with azithromycin was also reported in a retrospective study involving French patients. A total of 1061 SARS-CoV-2-positive patients treated with hydroxychloroquine (200 mg 3 times a day) in combination with azithromycin were included in the study (500 mg on day 1 followed by 250 mg daily for the next 4 days). Virologic cure and clinical outcomes were assessed. Approximately 92% of the patients experienced virologic cure (viral culture and RT-PCR), and 95% of the patients reported alleviation of clinical symptoms. Multivariate analysis revealed older age (odds ratio \[OR\] 1.11, 95% confidence interval \[CI\] 1.07--1.15), selective beta-blocking agents (OR 4.16, 95% CI 1.19--14.55), angiotensin II receptor blockers (OR 18.40, 95% CI 6.28--53.90) and medium and high national Early Warning Score (NEWS; OR 9.48, 95% CI 3.25--27.66; OR = 10.05, 95% CI 3.16--32.02, respectively) were significantly associated with poor clinical outcome. Cardiac toxicity was not reported in the study \[[@CR19]\]. Although cardiac toxicity was not reported in any of the studies, a study by Chorin et al. reported an extension of the QT interval in SARS-CoV-2-positive patients treated with hydroxychloroquine, suggesting a risk of arrhythmia \[[@CR20]\].

Despite the positive results favoring the usage of hydroxychloroquine with and without azithromycin in SARS-CoV-2-positive patients, a prospectively randomized study by Chen et al. reported a lack of significantly different virologic cure rates in patients treated with hydroxychloroquine compared with placebo. Other clinical end points such as time to body temperature normalization was also similar among the groups \[[@CR21]\]. In another prospective single-arm study conducted by Molina et al., 11 consecutive SARS-CoV-2-positive patients treated with hydroxychloroquine were followed up for the assessment of virologic and clinical outcomes. After 6 days of treatment, 80% of the patients remained virologically positive for SARS-CoV-2 by qualitative PCR, which was in contrast to the earlier studies \[[@CR17], [@CR21]\]. This was further reiterated in a recent study with a propensity-score-matched cohort of patients treated with either hydroxychloroquine alone or in combination with azithromycin or placebo. The rates of death were lower in those treated with placebo (11.4%) compared with those treated with hydroxychloroquine alone (27.8%) and those treated with hydroxychloroquine and azithromycin (22.1%). The risk of mechanical ventilation was similar in all the groups. Virologic cure and improvement in clinical outcomes were not assessed in this study \[[@CR23]\].

In a recent RCT, the efficacy of hydroxychloroquine was compared with standard of care. The study recruited 150 patients confirmed to be positive for SARS-CoV-2 and randomly treated with hydroxychloroquine plus standard of care (75 patients) and standard of care alone (75 patients). The primary end point was virologic cure after 28 days of treatment. Virologic cure probability by 28 days in hydroxychloroquine plus standard of care was 85.4% (95% confidence interval \[CI\] 73.8--93.8%), which was similar to that in the standard of care alone group (81.3%; 95% CI 71.2--89.6%) \[[@CR24]\]. A summary of the available evidence for hydroxychloroquine is provided in Table [1](#Tab1){ref-type="table"}.

Currently available early clinical evidence provides contradictory findings on the efficacy of hydroxychloroquine in SARS-CoV-2-positive patients. There are currently 125 clinical trials registered in the WHO International Clinical Trials Registry Platform (ICTRP; <https://clinicaltrials.gov/ct2/who_table>) and 192 studies registered in clinicaltrials.gov. The results of the ongoing studies will provide conclusive evidence on the efficacy of hydroxychloroquine in the treatment of SARS-CoV-2.

Remdesivir {#Sec10}
----------

Remdesivir is a nucleoside analog with proven activity against RNA viruses causing lethal hemorrhagic fever (Nipah and Ebola). It is an RNA-dependent RNA polymerase inhibitor capable of inhibiting multiple CoVs \[[@CR25]\]. In a mouse SARS virus experimental model, the administration of remdesivir 1 day after the infection reduced the virus titer in the lungs. Similar findings were also observed with a rhesus monkey model of MERV-CoV \[[@CR25]--[@CR27]\]. The pre-clinical efficacy of remdesivir was confirmed in in vitro studies with Vero E6 cell lines \[[@CR15]\].

The probable therapeutic effect of remdesivir in a patient with SARS-CoV-2 was initially reported in a case report wherein remdesivir was used on compassionate grounds. Although virologic improvement and clinical cure were observed in the patient, remdesivir was used only on the 6th day of admission, and the continuous viral load testing revealed that a reduction in viral load had begun before the administration of the drug. Hence, the observed clinical effect might be due to immunity and supportive treatment \[[@CR28]\]. A larger prospective cohort of patients treated with remdesivir on compassionate grounds was recently reported by Grein et al. \[[@CR29]\]. Of the 61 patients who received at least one dose of remdesivir, 53 patients were available for follow-up. After a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation. A total of 25 patients (47%) were discharged, and 7 patients (13%) died with a mortality of 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation \[[@CR29]\].

The efficacy of remdesivir was recently evaluated in an RCT involving Chinese patients compared with placebo. The study enrolled 237 patients (158 to remdesivir and 79 to placebo) and evaluated the clinical improvement up to day 28. The results of the study revealed a lack of significant difference in time to clinical improvement in patients treated with remdesivir compared with placebo (hazard ratio, 1.23 \[95% CI 0.87--1.75\]). In patients with symptoms for ≤ 10 days, remdesivir showed better efficacy (hazard ratio (HR), 1.52 \[95% CI 0.95--2.43\]), albeit without statistical significance \[[@CR30]\].

The early clinical evidence for the efficacy of remdesivir is inconclusive with only marginal efficacy. But owing to the differences in the end points considered in the studies, the precise role of remdesivir may require larger studies with the assessment of both virologic and clinical outcomes. At present, there are 22 trials registered in clinicaltrials.gov and 13 studies registered in the WHO-ICTRP.

Corticosteroids {#Sec11}
---------------

Corticosteroids are immune modulators that suppress the inflammatory response, thereby minimizing tissue damage. The early observational evidence for the effective use of corticosteroids stems from the lower prevalence of SARS-CoV-2 infection in patients with chronic respiratory disease, suggesting a role for the drugs given for chronic respiratory disease in reducing the prevalence of SARS-CoV-2 infections in such patients \[[@CR31]\]. The early pre-clinical evidence provided by Matsuyama et al. reported effective antiviral activity of ciclesonide in inhibiting the replication of SARS-CoV-2 in epithelial cell lines with an effective concentration of 6.3 µM \[[@CR32]\]. Despite the anti-inflammatory effect provided by corticosteroids, they also cause immune suppression, delaying viral clearance \[[@CR33]\].

A recent prospective cohort study conducted by Zha et al. recruited 31 SARS-CoV-2-positive patients treated with corticosteroids (11 patients) or supportive care. The study found no statistically significant association between treatment with corticosteroids and virus clearance time (HR 1.26; 95% CI 0.58--2.74), hospital length of stay (HR 0.77; 95% CI 0.33--1.78) or duration of symptoms (HR 0.86; 95% CI 0.40--1.83) \[[@CR34]\]. A recent meta-analysis also suggested a higher relative risk for mortality and longer length of stay in patients with SARS-CoV and MERS-CoV treated with corticosteroids \[[@CR35]\].

In a retrospective cohort study conducted by Wang et al., 46 SARS-CoV-2-positive patients treated with either corticosteroids \[[@CR25]\] or supportive care \[[@CR19]\] were analyzed for clinical outcomes. The mean duration for body temperature back to the normal range was significantly shorter in patients treated with corticosteroids compared with those without the administration of corticosteroids (2.06 ± 0.28 vs. 5.29 ± 0.70; *P* = 0.010). The patients included in the study had severe pneumonia and were treated early with a low dose of corticosteroid, suggesting a favorable effect of early, low-dose treatment \[[@CR36]\]. On the contrary, another observational study conducted by Lu et al. reported a limited effect of adjuvant treatment with corticosteroids in critically ill patients \[[@CR37]\].

The early clinical evidence for the treatment with corticosteroids remains inconclusive. There are 72 RCTs currently under progress to evaluate the efficacy of different corticosteroids at different stages of SARS-CoV-2 infection (clinicaltrials.gov).

Immunotherapy with Convalescent Plasma/Sera {#Sec12}
-------------------------------------------

The early evidence of the efficacy of convalescent plasma/sera was provided by two case series from China. In the first study, five critically ill patients with acute respiratory distress syndrome (ARDS) were administered convalescent plasma/sera containing neutralizing IgG antibody at a titer of \> 1:1000 that had been obtained from five patients previously recovered from SARS-CoV-2. All the patients were on mechanical ventilation at the time of treatment and previously treated with antiviral agents and methylprednisolone. After the treatment with convalescent plasm/sera, body temperature normalized after 3 days in four of the five patients, and viral loads also became negative after 12 days of treatment. ARDS was resolved in four patients after 12 days of treatment, and three patients were discharged \[[@CR38]\]. In another prospective case series, ten patients were treated with convalescent plasma/sera with a neutralizing antibody titer of \> 1:640. The radiologic examination revealed the resolution of lung lesions after 7 days and virologic cure in seven patients \[[@CR39]\]. These findings were also substantiated by a case report of two elderly patients treated with convalescent plasma/sera from South Korea. Both the patients had been previously treated with hydroxychloroquine and lopinavir/ritonavir. Both the patients experienced virologic cure after 3 days of treatment with convalescent plasma/sera. The resolution of lung lesions was also observed along with alleviation of other clinical symptoms \[[@CR40]\]. Although the evidence base for immunotherapy with convalescence plasma/sera is supported by only weak quality evidence, it holds promise for future management strategies.

Tocilizumab {#Sec13}
-----------

Previous studies on MERV-CoV and SARS-CoV-1 have revealed the release of a plethora of cytokines, including IL-6, which was also confirmed in SARS-CoV-2 infection \[[@CR41]\]. Hence, tocilizumab, which is a monoclonal antibody targeting IL-6, was explored as a treatment option in the treatment of cases with severe SARS-CoV-2 infection. The earliest evidence of its efficacy was provided from a case series by Xu et al. The study included 21 patients (17 severe and 4 critical) who were treated with tocilizumab. Irrespective of the disease severity, all the patients experienced normalization of body temperature 1 day after the treatment with tocilizumab. The oxygen saturation (SpO~2~) levels were also improved significantly, and one-third of patients on ventilator support were put on a noninvasive ventilator a day after the treatment. The percentage of lymphocytes and C-reactive proteins also returned to normal in most patients after 5 days of treatment \[[@CR41]\].

In a subsequent case report, tocilizumab was also used successfully for treating a patient with sickle cell anemia \[[@CR42]\]. The patient was hospitalized and, on day 1, developed symptoms of SARS-CoV-2 infection, including fever (38.5 °C) and SpO2 dropping to 91% with crackles at pulmonary auscultation. The patient was treated with antibiotics and hydroxychloroquine at a dosage of 200 mg orally every 8 h while the results of RT-PCR were awaited. The patient was treated with 1 pulse of intravenous tocilizumab at a dosage of 8 mg/kg on day 2 after the deterioration of symptoms and had a positive result in RT-PCR for SARS-CoV-2 infection. The patient experienced clinical cure with an improvement in SpO2 and was discharged on day 5 \[[@CR42]\]. The confounding effect of early hydroxychloroquine treatment cannot be ruled out as a possible cause of early clinical cure in this patient. Further clinical studies are required to substantiate the utility of tocilizumab in the treatment of SARS-CoV-2 patients.

Other Antiviral Drugs {#Sec14}
---------------------

Among the antiviral drugs, lopinavir, ritonavir and arbidol were explored in clinical studies involving SARS-CoV-positive patients. In a prospective cohort study conducted by Ye et al., 47 patients treated with either lopinavir/ritonavir or adjuvant treatment were analyzed for efficacy outcomes. The study reported favorable outcomes with respect to lowering body temperature in patients treated with lopinavir/ritonavir compared with adjuvant treatment alone \[[@CR43]\].

In a recent RCT, 50 patients with laboratory-confirmed COVID-19 were treated either with lopinavir/ritonavir (34 cases) or arbidol (16 cases). All the patients had mild-to-moderate SARS-CoV-2 infection without ARDS. The reduction in viral load was the primary end point. After 14 days of treatment, virologic cure was observed in all the patients treated with arbidol, but 15 (44.1%) patients treated with lopinavir/ritonavir still had detectable viral load. The study concluded the superior effect of arbidol over lopinavir/ritonavir in the treatment of cases with mild-to-moderate SARS-CoV infection \[[@CR44]\]. In another RCT, 86 patients with mild-to-moderate SARS-CoV-2 infection were randomly assigned to the lopinavir/ritonavir group \[[@CR33]\] or the arbidol group \[[@CR34]\] or the no antiviral drug group \[[@CR16]\] \[[@CR16]\]. The primary end point was virologic cure. The study reported similar rates and duration of virologic cure in all three groups, suggesting lack of clinical efficacy of antiviral drugs in the treatment of cases with mild-to-moderate SARS-CoV-2 infection \[[@CR45]\].

Early Evidence and Treatment Guidelines {#Sec15}
---------------------------------------

The treatment guidelines provided by different nodal governmental agencies are evidence-based and are subject to change based on the availability of newer evidence. They also take into account the local availability of drugs and evidence from studies done in specific geographies \[[@CR46]\]. Considering the evidence-based nature of treatment guidelines and their implications for patient care, we have included the different treatment guidelines and have also summarized the changes they have gone through mainly because of the evolution of the clinical evidence landscape. Early treatment guidelines were limited by their methodologic restrictions arising from the lack of quality clinical evidence.

Despite the poor quality of early evidence, multiple treatment options were recommended by different nodal agencies. WHO had published guidance document for the therapeutic management of COVID-19 patients in March 2020, which was updated in May 2020. The early treatment guideline released in March did not recommend any pharmacologic intervention except symptomatic management of COVID-19 patients \[[@CR47]\]. As per the recent guideline document from WHO, chloroquine/hydroxychloroquine, lopinavir/ritonavir, remdesivir, unifenovir, favipiravir, tocilizumab and plasma therapy are recommended only in the context of clinical trials and glucocorticoids are recommended in any treatment setting \[[@CR48]\]. Among the treatment options, hydroxychloroquine and chloroquine were provided emergency use authorization by the Food and Drug Administration (FDA) for the treatment of COVID-19 patients based on early evidence. However, based on the subsequent clinical evidence the early use authorizations provided for chloroquine and hydroxychloroquine were revoked as the adverse events outweighed the potential benefits \[[@CR49]\]. Similarly, remdesivir was also given emergency use authorization by the FDA \[[@CR50]\].

As per the National Institutes of Health (NIH) guidelines, chloroquine and hydroxychloroquine (with and without azithromycin) are not recommended for the treatment of COVID-19 patients except in clinical trial setting. With respect to remdesivir, the NIH guidelines recommends its use in hospitalized patients, and it should be used on priority to treat patients requiring supplemental oxygen. Furthermore, lopinavir and ritonavir were also not recommended for routine use in COVID-19 patients except in the context of clinical trials. The evidence base for convalescent plasma/sera is also not sufficient to recommend in favor of or against their use in the treatment of COVID-19 patients. Based on the recently published RECOVERY trial, NIH recommends the usage of dexamethasone in patients who either require supplemental oxygen or are on mechanical ventilation \[[@CR51]\].

As per the updated guidelines from the Infectious Diseases Society of America, hydroxychloroquine, chloroquine and azithromycin are recommended only in the setting of a clinical trial with a conditional recommendation with low certainty evidence. Similarly, lopinavir/ritonavir, convalescent sera and tocilizumab are also recommended only in the context of clinical trials, whereas corticosteroids are recommended only for severe COVID-19 patients in routine hospital settings. Corticosteroids are not recommended for the treatment of patients with mild-to-moderate SARS-CoV-2. Remdesivir is also recommended for treatment in patients with severe COVID-19 routine hospital settings \[[@CR52]\].

The treatment guidelines released by the Chinese National Health Commission have also undergone extensive evidence-based changes, and the recent 7th edition was published in March 2020. It recommended the use of α-interferon atomization inhalation (5 million units per time for adults in sterile injection water, twice a day) and lopinavir/ritonavir orally, two capsules each time twice a day, based on weak evidence. It also recommended 40--80 mg/day methylprednisolone based on weak evidence and tocilizumab, convalescent plasma/sera therapy and glucocorticoids were also recommended for treatment \[[@CR53]\].

The Directorate of Health Services, Government of India, had released multiple updated guideline documents pertaining to different aspects of COVID-19 including therapeutic management. As per the early management guidelines released in March, off-label use of hydroxychloroquine and azithromycin were recommended without any mention about specific target patient groups \[[@CR54]\]. Hydroxychloroquine was also recommended as chemoprophylaxis in high-risk healthcare workers and asymptomatic first-degree contacts as per an advisory released in March 2020. This recommendation was based on pre-clinical data, and the advisory was updated in May 2020 providing observational evidence on the lower incidence of COVID-19 in healthcare workers who were on prophylactic treatment with hydroxychloroquine \[[@CR55]\]. As per the recent evidence-based guidelines released in July, off-label use of hydroxychloroquine should be used after discussing the potential implications with patients and should be used in an early stage of disease. The available evidence is not sufficient to recommend against the use of hydroxychloroquine. Remdesivir was provided emergency use authorization and may be used in patients requiring supplemental oxygen. Convalescent plasma/sera could be considered in patients with progressive requirement for supplemental oxygen depending on the availability (4 to 13 ml/kg, usually 200 ml single dose given slowly over not less than 2 h). The guidelines also recommend off-label use of tocilizumab in mechanically ventilated patients. Unlike other guidelines, both the early and recent Indian guidelines recommend the use of glucocorticoids including dexamethasone in patients with progressive deterioration of oxygenation indicators \[[@CR56]\].

Apart from the above guidelines, multiple national guidelines have been released by the affected countries based on available evidence, consensus and local availability. Accordingly Russian guidelines recommend lopinavir/ritonavir, recombinant interferon and ribavirin in moderate-to-severe infections; French guidelines recommend lopinavir/ritonavir and hydroxychloroquine; Dutch guidelines recommend chloroquine, lopinavir/ritonavir and a combination of chloroquine with remdesivir and lopinavir/ritonavir in severe disease \[[@CR57]\]. The evidence base for most of these recommendations is not strong, and most of these guidelines did not grade the evidence based on the GRADE rating.

Recent Evidence {#Sec16}
---------------

Apart from the early clinical evidence, two RCTs evaluating dexamethasone and remdesivir were published recently, after our literature search time period. But we have included the trials as they also constitute an evidence base for recent therapeutic management guidelines. Since most of the early studies did not use all-cause mortality as a composite end point, the RECOVERY trial utilized all-cause mortality to evaluate the efficacy of dexamethasone, a glucocorticoid, compared to standard of care. Glucocorticoids are not recommended by multiple therapeutic management guidelines owing to lack of evidence and the profound immunosuppressive effects \[[@CR57]\]. The RECOVERY trial randomized a total of 6425 patients to receive either dexamethasone (*n* = 2104) or standard of care (*n* = 4321). The rates of all-cause mortality were significantly lower in the dexamethasone arm compared to standard of care (22.9 vs. 25.7; rate ratio: 0.83; *P* \< 0.0001). The study recruited patients with different baseline severity levels, and a prespecified subgroup analysis revealed significant reduction in all-cause mortality only in patients requiring respiratory support at randomization. This is in line with the anti-inflammatory activity of dexamethasone, which might be pronounced and beneficial only during specific stages of the disease. In early-stage SARS-CoV 2-positive patients, dexamethasone might alter the natural disease course \[[@CR58]\].

Recently, the preliminary results of the Adaptive Covid-19 Treatment Trial (ACTT-1) that evaluated the efficacy of remdesivir in the treatment of SARS-CoV was published. The trial randomized 1063 patients to receive either remdesivir (*n* = 541) or placebo (*n* = 522) and evaluated the time to recovery with an eight-stage ordinal scale based on the clinical condition at randomization. The overall rate ratio for recovery after adjusting for baseline ordinal scores was found to significantly favor remdesivir with an effect estimate of 1.31 (*P* \< 0.0001). Across different ordinal score categories, a significant recovery rate ratio was observed only for patients with an ordinal score of 5 (hospitalized, requiring any supplemental oxygen). The HR for mortality was also significantly favoring the remdesivir group only for patients with an ordinal score of 5 (HR 0.22, 95% CI 0.08, 0.58). However, in the overall population, there was no significant reduction in mortality in the remdesivir arm (HR 0.70; 95% CI 0.47, 1.04) \[[@CR59]\].

Perspectives on Early Clinical Evidence {#Sec17}
---------------------------------------

The normal workflow in the development of treatment options for any indication involves pre-clinical to early clinical to late stage clinical trials. However, the normal workflow is hampered in case of pandemics. Based on the early evidence, the therapeutic options available were drugs attenuating either the immunologic response (anti-inflammatory drugs) or the viral load (antiviral agents). Since the pathogenesis of SARS-CoV-2 involves mainly inflammatory responses, the most promising drugs are anti-inflammatory drugs. The inflammatory response is also related to the viral load, which makes the selection of the ideal end point difficult. From the early evidence and from the trials in the pipeline, the most common end points assessed were a 6- or a 7-point ordinal scale outcome that defines clinical benefit based on the baseline clinical condition till the end of the study or death, whichever is earlier. Depending on the study, a 2- or 3-point decrease in the selected ordinal scale was considered a marker of clinical efficacy. However, overall mortality might be the ideal composite end point that represents clinical benefit in a pandemic outbreak. On the contrary, overall mortality might not take into account the initial patient status, thereby confounding the results. In the prevailing scenario, ordinal-scale end points as a marker of clinical improvement and virologic cure might be robust indicators of clinical improvement, but a consensus on the ordinal scale with respect to patients with different severities of diseases might help in selecting the optimum therapeutic management strategy based on clinical evidence \[[@CR60]\].

A case in point is the issue with the real-world evidence on the efficacy of hydroxychloroquine \[[@CR61]\]. This was a multi-national registry-based study, which was among the earliest evidence in support of hydroxychloroquine for the treatment of SARS-CoV-2. However, subsequent clinical trials provided contradictory results that led to the questioning of the results of the study and subsequent journal retraction. In our systematic literature review, this study was also considered as this was early clinical evidence. The availability of preprint servers also plays a huge role in dissemination of early-stage evidence, which is a milieu never faced in the past. Although this leads to faster dissemination, it can also lead to propagation of junk science. We have also included evidence from preprint servers to make a comprehensive appraisal of early-stage evidence. Subsequent to the retraction of the Lancet study on hydroxychloroquine, the French study published in the preprint server MedRxiv was also withdrawn. Unlike the journal retractions, preprint retractions do not require substantial explanation of the reasons for retraction. This further complicates the quality of early evidence \[[@CR62]\].

Future Recommendations {#Sec18}
----------------------

The early-stage evidence available does not provide convincing support in favor of or against a particular therapeutic regimen. This is mainly because of the heterogeneity with respect to the patients, pathogen variants and end points. Considering the fact that the last few pandemics were caused by respiratory viruses, drafting a consensus on the most appropriate end point will help in improving the quality of evidence in future pandemics. Furthermore, despite the availability of RCTs, they were of low quality because of the inherent bias (no data on blinding) and imprecision. Since the field of evidence-based medicine is a dynamically evolving field, future studies, especially studies of importance in dealing with medical emergencies, should be appropriately designed to provide reliable and timely evidence. Although the availability of preprint servers facilitates faster dissemination of data, the non-peer-reviewed nature of content needs to be interpreted with caution.

Vaccines hold great promise for the management and control of COVID 19. Currently, 42 vaccine candidates are under clinical development sponsored by academic, industry and governmental agencies. Out of 42 candidate vaccines, 24 vaccine candidates are in phase 1--3 clinical development (Table [3](#Tab3){ref-type="table"}) \[[@CR63]\].Table 3Treatment recommendation from different guidelines and an update on COVID-19 vaccinesGuidelineDrugs recommendedContextContraindicationsWHO, May, 2020Chloroquine/hydroxychloroquine, lopinavir/ritonavir, remdesivir, unifenovir, favipiravir, tocilizumab and plasma therapyOnly in the context of RCTsNo specific recommendation because of lack of evidenceGlucocorticoidsIn routine settingsCOVID-19 Treatment Guidelines Panel, National Institute of Health, updated, July, 2020RemdesivirHospitalized patientsNo specific recommendation because of lack of evidenceDexamethasonePatients requiring supplemental oxygenLopinavir/ritonavirOnly in the context of RCTsGuidelines for treatment and management of patients with COVID-19, Infectious Diseases Society of America, updated June, 2020Hydroxychloroquine/chloroquine/azithromycinOnly in the context of RCTsNo specific recommendation because of lack of evidenceLopinavir/ritonavirOnly in the context of RCTsConvalescent seraOnly in the context of RCTsTocilizumabOnly in the context of RCTsCorticosteroidsPatients with Severe COVID-19, onlyChinese national health commission, 7th edition, March, 2020α-Interferon atomization inhalationBased on severityNo specific recommendation because of lack of evidenceLopinavir/ritonavirMethylprednisoloneRevised Guidelines on Clinical Management of COVID-19, Indian National Guideline, July, 2020Corticosteroids including dexamethasonePatients with progressive deterioration of lung functionEarly pregnancy should be terminatedRemdesivirPatients requiring supplemental oxygenConvalescent plasma/seraPatients with progressive requirement of oxygenTocilizumabMechanically ventilated patientsCurrent status of COVID-19 vaccinesVaccine candidateSponsorTrial phaseInactivated vaccineWuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)Phase 3CoronaVacSinovacPhase 3Bacillus Calmette-Guerin (BCG) live-attenuated vaccineUniversity of Melbourne and Murdoch Children's Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General HospitalPhase 2/3AZD1222The University of Oxford; AstraZeneca; IQVIAPhase 2/3mRNA-1273ModernaPhase 2Ad5-nCoVCanSinoBiologicsPhase 2Adjuvant recombinant vaccine candidateAnhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of SciencesPhase 2BNT162Pfizer, BioNTechPhase 1/2BBIBP-CorVBeijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)Phase 1/2GX-19GenexinePhase 1/2Gam-COVID-VacGamaleya Research Institute, Acellena Contract Drug Research and DevelopmentPhase 1/2Self-amplifying RNA vaccineImperial College LondonPhase 1/2LUNAR-COV19Arcturus Therapeutics and Duke-NUS Medical SchoolPhase 1/2ZyCoV-DZydus CadilaPhase 1/2INO-4800Inovio PharmaceuticalsPhase 1mRNA-based vaccineCureVacPhase 1SCB-2019GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen InnovaxPhase 1COVAX-19Vaxine Pty LtdPhase 1NVX-CoV2373NovavaxPhase 1Plant-based adjutant COVID-19 vaccine candidateMedicago; GSK; DynavaxPhase 1Molecular clamp vaccineCSL; The University of QueenslandPhase 1CovaxinBharat Biotech; National Institute of VirologyPhase 1bacTRL-SpikeSymvivoPre-clinicalPittCoVaccUPMC/University of Pittsburgh School of MedicinePre-clinicalMeasles vector vaccineUniversity of Pittsburgh's Center for Vaccine ResearchPre-clinicalIi-Key peptide COVID-19 vaccineGenerex BiotechnologyPre-clinicalRecombinant vaccineVaxartPre-clinicalLineaDNATakis BiotechPre-clinicalAd26.COV2-SJohnson & JohnsonPre-clinicalAdCOVIDAltimmunePre-clinicalT-COVIDTMAltimmunePre-clinicalProtein subunit vaccineUniversity of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine CentrePre-clinicalRecombinant vesicular stomatitis virus (rVSV) vaccineMerck; IAVIPre-clinicalAdenovirus-based vaccineImmunityBio; NantKwestPre-clinicalAAVCOVIDMassachusetts Eye and Ear; Massachusetts General Hospital; University of PennsylvaniaPre-clinicalRecombinant vaccineSanofi, Translate BioPre-clinicalHaloVaxVoltron Therapeutics, Inc.; Hoth Therapeutics, IncPre-clinicalmRNA-based vaccineChulalongkorn University's Center of Excellence in Vaccine Research and DevelopmentPre-clinicalHDT-301University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio CorpPre-clinicalmRNA lipid nanoparticle (mRNA-LNP) vaccineCanSino Biologics, Precision NanoSystemsEarly research*RCTs* Randomized controlled trials, *WHO* World Health Organization

Conclusion {#Sec19}
==========

The current evidence base available for different treatment options provides ambiguous results mainly because of the study designs and the end points assessed. This is also reflected in the different national treatment guidelines that were based on relatively weak evidence. The systematic review highlighted the lacuna and methodologic deficiency in early clinical evidence and an update on different therapeutic management guidelines. The results of the ongoing clinical studies and well-designed real-world studies will improve the evidence base and may lead to further evolution of treatment guidelines with the addition of more therapeutic options. Furthermore, a consensus on the appropriate end points for efficacy in different categories of patient may also improve the quality of evidence in case of future pandemics of respiratory viruses.
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